论文部分内容阅读
2012年11月27日,AesRx公司宣布将于美国血液病学会上公布近期完成的抗镰状细胞贫血症药物Aes-103的I期试验数据。镰状细胞贫血症是一种遗传性血红蛋白分子功能紊乱疾病,患者血红蛋白发生聚合,红细胞扭曲变形成镰状,携带氧的功能只有正常红细胞的一半,临床表现为慢性溶血性
On November 27, 2012, AesRx Inc. announced that it will release Phase I trial data from Aes-103, a recently completed anti-sickle cell anemia drug, at the American Society of Hematology. Sickle cell anemia is a hereditary disorder of hemoglobin molecules, patients with hemoglobin polymerization, red blood cells twisted into sickle-shaped, oxygen carrying function is only half of normal red blood cells, the clinical manifestations of chronic hemolytic